Devic

Yachting: At the Yacht Club de Monaco the YCM Awards - Trophée Credit Suisse ceremony

Retrieved on: 
Thursday, December 22, 2022
Devic, Club, YCM, Research, Royal Yacht Squadron, ILCA, RC44, The Ocean Race, Classification, Pleasure, Yacht club, Ministry of Education (Malaysia), Route du Rhum, Climate change, Environment, HSH, Entertainment, Antarctica, Optimism

The Yacht Club de Monaco gathered for the traditional winter cocktail party at the presence of his President H.S.H.

Key Points: 
  • The Yacht Club de Monaco gathered for the traditional winter cocktail party at the presence of his President H.S.H.
  • "It's an occasion for different generations to share their passion of the sea and everyone has its own way to living that passion.
  • In 2022, YCM was also active offshore with two members on the start of the 12th Route du Rhum – Destination Guadeloupe.
  • The celebration allowed them to be honored at the YCM Awards – Credit Suisse Trophy.

Devic's Syndrome Treatment Global Market Report 2022: Soliris (Eculizumab) to Fuel Considerable Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Health, Other Health, Death, Antibody, Woman, Alexion, Neuromyelitis optica spectrum disorder, Autoantibody, C5a, Inflammation, CNS, Degenerative disease, DST, Population, Neuron, Diagnosis, Growth, Complement component 5, Geography, Brain, Prevalence, Chapter Five, Chapter Three, Pain, MedImmune, Plasma protein binding, Patient, National Multiple Sclerosis Society, Spectrum disorder, Autoimmune disease, Severe cognitive impairment, Syndrome, Awareness, CAGR, Chapter Six, Spinal cord, Protein, Type, Chugai Pharmaceutical Co., Optic nerve, NMOSD, Immune system, Paralysis, Lithium, Vaccine, Fine chemical, Pharmaceutical industry, Medical imaging, Fertilizer, Eculizumab, Devic

The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.

Key Points: 
  • The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.
  • This report comprises in-depth information related to the Devic's Syndrome treatment market along with major factors affecting or assisting market such as opportunities, drivers, & restraints.
  • This report covered detailed info related to the global Devic's syndrome treatment market segmented based on drug type, and geography.
  • Global Devic's Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
    Chapter 4.

Global Neuromyelitis Optica (Devic's Syndrome) Clinical Trials Market Research Report, H2 2021 Review - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 1, 2021
Health, General Health, Spectrum disorder, Decision-making, Trial, Devic, Pharmaceutical industry

The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides an overview of Neuromyelitis Optica (Devic's Syndrome) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome) .
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

BioTek reMEDys Expands its Specialty Therapeutics Portfolio to Include UPLIZNA

Retrieved on: 
Thursday, November 4, 2021
Infectious Diseases, Pharmaceutical, Health, Population, Pharmacy, Myelitis, Conditional sentence, Cognitive remediation therapy, Spinal cord, Inflammation, NMOSD, Therapy, Optic neuritis, Neuromyelitis optica spectrum disorder, DE, Optic nerve, Devic, Patient, Brain, Pharmaceutical industry

BioTek reMEDys, one of the nations largest specialty infusion pharmacies focused on rare diseases, has announced the addition of UPLIZNA to its specialty therapeutics portfolio to provide treatment to a broader patient population and further expand upon its diverse pharmaceutical product offering.

Key Points: 
  • BioTek reMEDys, one of the nations largest specialty infusion pharmacies focused on rare diseases, has announced the addition of UPLIZNA to its specialty therapeutics portfolio to provide treatment to a broader patient population and further expand upon its diverse pharmaceutical product offering.
  • By adding UPLIZNA to its extensive portfolio of life-saving specialty therapies, BioTek reMEDys is furthering its commitment to respond to the needs of and requests of patients and their loved ones.
  • UPLIZNA is a prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.
  • Founded in 2011, BioTek reMEDys, based in New Castle, DE, has become one of the nations largest independent infusion pharmacies focused on home infusion and infusion suites.

H1 2021 Neuromyelitis Optica (Devic's Syndrome) Global Clinical Trials Review - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Neurological disorders, Health sciences, Health, Autoimmune diseases, Devic, Central nervous system disorders, Clinical trial, Neuromyelitis optica spectrum disorder, Myelitis, NMO

The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Neuromyelitis Optica (Devic's Syndrome) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome) .
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Neuromyelitis Optica (Devic's Syndrome) Pipeline Review, H2 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 10, 2020
Pharmaceutical, Health, Optical, Neurological disorders, Autoimmune diseases, Central nervous system, Nervous system, Devic, Neuromyelitis optica, Myelitis, Edgley Optica, Multiple sclerosis, Optic-spinal MS

The "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Neuromyelitis Optica - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder

Retrieved on: 
Tuesday, August 27, 2019
Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Autoimmune diseases, Medicine, Organ systems, Medical specialties, Multiple sclerosis, Rare diseases, Neuromyelitis optica, Inebilizumab, Devic, NMO, Myelitis, Placebo, Neuromyelitis Optica Spectrum Disorders (NMOSD), Inebilizumab, N-MOmentum, Viela Bio

The safety and efficacy results provided in the application are from the pivotal N-MOmentum trial, the largest global, placebo-controlled study in NMOSD.

Key Points: 
  • The safety and efficacy results provided in the application are from the pivotal N-MOmentum trial, the largest global, placebo-controlled study in NMOSD.
  • In addition, inebilizumab impacted measurements of worsening disability, hospitalizations and new central nervous system MRI lesions.
  • NMOSD is a recently proposed unifying term for neuromyelitis optica (NMO) also known as Devics disease and related syndromes.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make.

Viela Bio Announces Pivotal Study Results of Inebilizumab in NMOSD to be Presented in a Plenary Session at the 2019 American Academy of Neurology Annual Meeting

Retrieved on: 
Thursday, March 7, 2019
Health, Biotechnology, Clinical trials, Genetics, Infectious diseases, Pharmaceutical, Research, FDA, Science, Medical specialties, Branches of biology, Medicine, Autoimmune diseases, Monoclonal antibodies, Antibodies, Inebilizumab, Neuromyelitis optica, Glycoproteins, Aquaporin 4, Autoantibody, Devic

Viela Bio today announced that data from a pivotal study of its anti-CD19 monoclonal antibody inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD), were selected for presentation during the Clinical Trials Plenary Session at the 2019 American Academy of Neurology (AAN 2019) Annual Meeting.

Key Points: 
  • Viela Bio today announced that data from a pivotal study of its anti-CD19 monoclonal antibody inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD), were selected for presentation during the Clinical Trials Plenary Session at the 2019 American Academy of Neurology (AAN 2019) Annual Meeting.
  • NMOSD is a recently proposed unifying term for neuromyelitis optica (NMO)also known as Devics diseaseand related syndromes.
  • NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that can be fatal.
  • These AQP4-IgG autoantibodies are produced by plasmablasts and plasma cells and bind primarily to astrocytes in the central nervous system.